Isabelle Cohen-Codar

570 total citations
15 papers, 390 citations indexed

About

Isabelle Cohen-Codar is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Isabelle Cohen-Codar has authored 15 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 14 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in Isabelle Cohen-Codar's work include HIV Research and Treatment (14 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (10 papers). Isabelle Cohen-Codar is often cited by papers focused on HIV Research and Treatment (14 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (10 papers). Isabelle Cohen-Codar collaborates with scholars based in France, United States and Poland. Isabelle Cohen-Codar's co-authors include Jade Ghosn, Philippe Flandre, Jean‐François Delfraissy, Constance Delaugerre, Michael Norton, Christine Rouzioux, Marie‐Laure Chaix, François Raffi, Anne‐Marie Taburet and Pierre‐Marie Girard and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Bone.

In The Last Decade

Isabelle Cohen-Codar

15 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabelle Cohen-Codar France 13 355 312 107 37 19 15 390
Elisabetta Chiesa Italy 11 306 0.9× 242 0.8× 96 0.9× 63 1.7× 11 0.6× 17 351
David Shamblaw United States 6 341 1.0× 239 0.8× 143 1.3× 48 1.3× 14 0.7× 7 379
David Piontkowsky United States 12 422 1.2× 269 0.9× 206 1.9× 77 2.1× 20 1.1× 27 458
Anita Scribner United States 6 203 0.6× 156 0.5× 62 0.6× 48 1.3× 7 0.4× 7 245
Cédrick Wallet France 6 177 0.5× 158 0.5× 102 1.0× 45 1.2× 24 1.3× 9 242
Gianmaria Baldin Italy 13 387 1.1× 294 0.9× 124 1.2× 84 2.3× 20 1.1× 50 457
Corine Chazallon France 6 284 0.8× 214 0.7× 79 0.7× 53 1.4× 22 1.2× 12 320
Margaret A Bedison United States 7 291 0.8× 343 1.1× 51 0.5× 52 1.4× 25 1.3× 8 376
Antonella d'Arminio-Monforte Italy 10 329 0.9× 331 1.1× 55 0.5× 64 1.7× 16 0.8× 14 387
Bernhard Haas Austria 9 173 0.5× 113 0.4× 65 0.6× 69 1.9× 55 2.9× 12 262

Countries citing papers authored by Isabelle Cohen-Codar

Since Specialization
Citations

This map shows the geographic impact of Isabelle Cohen-Codar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Cohen-Codar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Cohen-Codar more than expected).

Fields of papers citing papers by Isabelle Cohen-Codar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Cohen-Codar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Cohen-Codar. The network helps show where Isabelle Cohen-Codar may publish in the future.

Co-authorship network of co-authors of Isabelle Cohen-Codar

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Cohen-Codar. A scholar is included among the top collaborators of Isabelle Cohen-Codar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Cohen-Codar. Isabelle Cohen-Codar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Tran, Tú-Anh, Jade Ghosn, Véronique Avettand-Fènoël, et al.. (2015). Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. Journal of Antimicrobial Chemotherapy. 70(9). 2627–2631. 4 indexed citations
2.
Vassallo, Matteo, J. Durant, Christine Lebrun‐Frénay, et al.. (2015). Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation. HIV Medicine. 16(7). 431–440. 26 indexed citations
3.
Mbisa, Jean L., Jade Ghosn, Marie‐Laure Chaix, et al.. (2014). Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes. Journal of Antimicrobial Chemotherapy. 69(12). 3340–3348. 12 indexed citations
4.
Briot, Karine, S. Kolta, Philippe Flandre, et al.. (2011). Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies. Bone. 48(5). 1133–1139. 21 indexed citations
5.
Ghosn, Jade, Constance Delaugerre, Philippe Flandre, et al.. (2011). Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen. PLoS ONE. 6(9). e24798–e24798. 29 indexed citations
6.
Kolta, S., Philippe Flandre, Isabelle Cohen-Codar, et al.. (2011). Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial. Current HIV Research. 9(1). 31–39. 15 indexed citations
7.
Avettand-Fènoël, Véronique, Philippe Flandre, Marie‐Laure Chaix, et al.. (2010). Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. Journal of Antimicrobial Chemotherapy. 65(5). 1005–1007. 16 indexed citations
8.
9.
Delaugerre, Constance, Philippe Flandre, Marie‐Laure Chaix, et al.. (2009). Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy. Antimicrobial Agents and Chemotherapy. 53(7). 2934–2939. 43 indexed citations
10.
Ghosn, Jade, Philippe Flandre, Isabelle Cohen-Codar, et al.. (2009). Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial*. HIV Medicine. 11(2). 137–142. 31 indexed citations
11.
Flandre, Philippe, Constance Delaugerre, Jade Ghosn, et al.. (2009). Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone. Antiviral Therapy. 14(1). 93–97. 14 indexed citations
12.
Ghosn, Jade, Marie‐Laure Chaix, Gilles Peytavin, et al.. (2008). Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. Journal of Antimicrobial Chemotherapy. 61(6). 1344–1347. 29 indexed citations
13.
Delfraissy, Jean‐François, Philippe Flandre, Constance Delaugerre, et al.. (2008). Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS. 22(3). 385–393. 100 indexed citations
14.
Spire, Bruno, Fabienne Marcellin, Isabelle Cohen-Codar, et al.. (2008). Effect of Lopinavir/Ritonavir Monotherapy on Quality of Life and Self-Reported Symptoms among Antiretroviral-Naive Patients: Results of the MONARK Trial. Antiviral Therapy. 13(4). 591–599. 11 indexed citations
15.
King, Martin, Richard A. Rode, Isabelle Cohen-Codar, et al.. (2007). Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy. 51(9). 3067–3074. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Chiesa Breakdown of academic impact, for papers by David Shamblaw Breakdown of academic impact, for papers by David Piontkowsky Breakdown of academic impact, for papers by Anita Scribner Breakdown of academic impact, for papers by Cédrick Wallet Breakdown of academic impact, for papers by Gianmaria Baldin Breakdown of academic impact, for papers by Corine Chazallon Breakdown of academic impact, for papers by Margaret A Bedison Breakdown of academic impact, for papers by Antonella d'Arminio-Monforte Breakdown of academic impact, for papers by Bernhard Haas
Rankless by CCL
2026